Free T4 Index (T7): The Legacy Correction for Binding-Protein Noise

What the Free T4 Index (T7) actually estimates

The Free T4 Index (T7) is a calculated estimate of free thyroxine activity. It multiplies total T4 by the T3 uptake (or thyroid hormone binding ratio, THBR) to correct for variation in thyroxine-binding globulin (TBG) — the main carrier protein for thyroid hormone in blood. The result is a unitless index that approximates the biologically available hormone fraction. Because the calculation depends on the specific T3 uptake or THBR assay a laboratory uses, T7 values are method-dependent and reference ranges vary by lab.

Why total T4 alone misleads when binding proteins shift

Most T4 travels bound to TBG and albumin; only a small unbound fraction reaches tissues and drives metabolic effects. That free fraction is what cells actually respond to — the free hormone hypothesis. Total T4 measures the entire pool, bound and free together, so it rises whenever TBG rises, even if the free fraction is unchanged.

Estrogen — from pregnancy, oral contraceptives, or hormone therapy — increases TBG, pushing total T4 upward without any change in thyroid output. Androgen therapy and nephrotic syndrome do the opposite, lowering TBG and pulling total T4 down. In both cases, total T4 alone gives a misleading picture. T3 uptake moves in the opposite direction to TBG: when TBG is high and binding sites are crowded, less T3 binds to the resin, so T3 uptake falls; when TBG is low, T3 uptake rises. Multiplying total T4 by this counter-signal cancels out the TBG effect and produces the T7 index.

Stress, illness, and heavy training load also tug on this system. Severe illness can shift T4-to-T3 conversion, alter protein binding, and change assay behavior. Overreaching without adequate recovery can mimic a low-T3 state. These influences mean any single T7 value can shift for reasons unrelated to thyroid disease, which is why T7 is always interpreted alongside TSH and clinical context.

How T7 is derived from total T4 and T3 uptake

The Free T4 Index (T7) was developed before direct free T4 immunoassays were widely available. It multiplies total T4 by a correction factor derived from T3 uptake (or the Thyroid Hormone Binding Ratio, THBR) to cancel out the effect of TBG variation — producing a unitless index that approximates the free fraction.

Free T4 Index (T7): Total T4 (µg/dL) × T3 Uptake (or THBR, expressed as a decimal fraction)

Example: If Total T4 = 8.5 µg/dL and T3 Uptake = 0.38, then T7 = 8.5 × 0.38 = 3.23 (unitless index).

Typical reference range: approximately 1.2–4.9 (varies by laboratory and assay — always use the reference range provided by the reporting lab).

No fasting is required for thyroid panels. Biotin supplements can cause falsely high T4 and falsely low TSH on many modern immunoassay platforms — the T3 uptake used in T7 calculation is less prone to biotin interference on classic resin assays, but modern platforms vary. Pause biotin supplementation for at least 48 hours before the draw when testing includes any thyroid markers.

A worked example illustrates why the correction matters: a pregnant woman with Total T4 of 14.2 µg/dL (which looks elevated against a non-pregnant reference range) and a T3 Uptake of 0.28 (low, because high estrogen-driven TBG binds more T3 out of the resin) yields T7 = 14.2 × 0.28 = 3.98 — within the normal index range, confirming that the elevated total T4 is a binding-protein artifact, not true thyroid excess. The same calculation logic applies during oral estrogen therapy or liver disease.

Reading a T7 result alongside your TSH

Reference intervals for T7 are built from large populations of apparently healthy people, not personal baselines. There is no single universal range: each laboratory validates its own method and scale, and the final index is unitless and method-dependent. Age, pregnancy, liver disease, and certain medications can shift interpretation without indicating thyroid disease.

The following patterns describe how T7 results typically align with thyroid physiology when read together with TSH:

• T7 below lab normal with rising TSH: consistent with primary hypothyroid physiology — the thyroid is underproducing hormone and the pituitary is compensating by raising TSH.
• T7 low-normal with rising TSH: a subclinical hypothyroidism pattern; free hormone is still within range but the pituitary signal suggests early insufficiency.
• T7 within lab normal: method-dependent; interpret in the context of TSH and symptoms rather than as a standalone reassurance.
• T7 high-normal with suppressed TSH: a hyperthyroid risk signal; the pituitary is already responding to excess free hormone even if the index has not crossed the upper limit.
• T7 elevated with suppressed TSH: consistent with hyperthyroid physiology — patterns seen in Graves' disease, toxic nodule, or excess thyroid hormone replacement.

A TBG-confounding caveat applies throughout: familial dysalbuminemic hyperthyroxinemia can elevate total T4 and distort T7 in ways that do not reflect true tissue hormone status. Non-thyroidal illness can alter protein binding and assay behavior independently of thyroid function. In these scenarios, pairing T7 with TSH and, when needed, a direct free T4 by equilibrium dialysis gives a more reliable read.

Guidelines from endocrine societies favor direct free T4 measurement when available, using T7 as a backup when binding protein changes or assay interferences complicate interpretation. Because T7 is method-dependent, comparing a result against prior values from the same lab and assay is more informative than comparing against a single population cutpoint.

What moves binding-protein levels and skews T7

TBG and protein-binding shifts. Estrogen — from pregnancy, oral contraceptives, or hormone replacement therapy — raises TBG, inflating total T4 and pulling T3 uptake down; T7 partially corrects for this but may still be influenced at extremes. Androgen therapy, nephrotic syndrome, and significant liver disease lower TBG, reducing total T4 and pushing T3 uptake up. Because T7 is built on the assumption that TBG variation is the dominant binding-protein change, conditions that alter albumin binding or introduce abnormal binding proteins (such as familial dysalbuminemic hyperthyroxinemia) can cause the index to over- or under-correct.

Assay interferences. High-dose biotin supplementation can cause falsely elevated T4 and falsely suppressed TSH on many modern immunoassay platforms; classic resin-based T3 uptake is less susceptible, but modern automated platforms vary. Heparin can artifactually elevate free hormone measurements in some assays. Heterophile antibodies — endogenous antibodies that cross-react with assay reagents — can produce spurious results across multiple thyroid markers simultaneously.

Nutritional cofactors of thyroid hormone synthesis and conversion. Thyroid hormone synthesis depends on adequate iodine; conversion of T4 to the more active T3 relies on selenium-dependent deiodinase enzymes. Iron supports the peroxidase machinery that builds thyroid hormone, and deficiency can blunt synthesis and action even before anemia develops. Prolonged severe caloric restriction can reduce T4-to-T3 conversion as a metabolic conservation response, lowering free T3 without necessarily shifting T7 substantially. Circadian consistency is associated with calmer hypothalamic–pituitary–thyroid (HPT) axis rhythms, while chronic sleep restriction can nudge TSH timing and alter next-day readings.

Medications and conditions that shift TBG or thyroid hormone production. Amiodarone alters both thyroid hormone production and peripheral conversion, and can skew multiple thyroid markers simultaneously. Glucocorticoids and certain anticonvulsants affect binding proteins and hormone metabolism. Iodine-containing contrast agents and lithium can push the thyroid gland itself toward hypo- or hyperfunction. Because of these moving parts, any T7 result should be reviewed in the context of current medications and recent procedures.

Thyroid markers that confirm the T7 signal

• TSH (thyroid-stimulating hormone): the pituitary signal that drives thyroid production. TSH responds log-linearly to small changes in free hormone, making it the most sensitive first-line marker for thyroid dysfunction. T7 is always interpreted alongside TSH — neither marker is sufficient alone.
• Total T4: the numerator of the T7 calculation. Understanding total T4 levels alongside TBG status explains why T7 differs from the apparent total and whether a high or low total T4 reflects true hormone change or a binding-protein shift.
• Free T3: the most biologically active thyroid hormone. Conversion from T4 to T3 can be impaired in illness, caloric restriction, or selenium deficiency. Free T3 provides a downstream view of hormone action that T7 does not capture.
• T3 uptake (THBR): the correction factor in the T7 formula. Because T3 uptake moves in the opposite direction to TBG, understanding its value helps explain why T7 diverges from total T4 in any given clinical situation.
• TPO antibodies (thyroid peroxidase antibodies): a marker of autoimmune thyroid disease. Elevated TPO antibodies alongside a falling T7 and rising TSH confirm Hashimoto's thyroiditis rather than a TBG-artifact explanation for low thyroid hormone levels.

Retesting T7 after a thyroid dose change

After a thyroid medication dose change — whether levothyroxine or an antithyroid drug — steady-state is achieved at approximately 4–6 weeks. Retesting before 4 weeks produces a T7 that does not yet reflect the true treated state and can prompt unnecessary further adjustments. The recommended retest window is 6–8 weeks after any dose change.

For healthy adults with no known thyroid condition, annual thyroid screening is sufficient. For those on levothyroxine or antithyroid medication, test at 6–8 weeks after each dose adjustment, then move to a longer interval once stable.

Standardize draw conditions for meaningful trend comparisons: same time of day (morning is preferred, as TSH has a circadian rhythm), biotin supplementation paused for at least 48 hours, and the same laboratory and assay method used for each successive result. T7 is a calculated index — if the lab changes its T3 uptake assay or recalibrates its platform, values may shift without any underlying change in thyroid function, making same-lab consistency especially important for longitudinal tracking.

When a T7 result warrants endocrine evaluation

Several patterns in T7 results, particularly when paired with TSH, indicate that clinical follow-up is appropriate rather than watchful waiting.

• A persistently elevated T7 with suppressed TSH — especially alongside symptoms such as palpitations, heat intolerance, tremor, or unintentional weight loss — is consistent with hyperthyroidism and warrants evaluation for Graves' disease, toxic nodule, or excess replacement. Subclinical hyperthyroidism (suppressed TSH with T7 still within range) carries an elevated risk of atrial fibrillation and accelerated bone loss with prolonged duration, which adds urgency to follow-up even when symptoms are absent.
• A persistently low T7 with rising TSH — particularly with fatigue, cold intolerance, weight gain, or dyslipidemia — is consistent with hypothyroidism. Untreated hypothyroidism is associated with elevated LDL cholesterol and cardiovascular risk; early identification allows timely intervention.
• A discordant pattern — for example, a high T7 with a normal or elevated TSH, or a low T7 with a suppressed TSH — suggests either a binding-protein artifact, assay interference, or a central (pituitary/hypothalamic) thyroid disorder, all of which require specialist evaluation.

T7 is unreliable and potentially misleading in several specific situations where direct free T4 by equilibrium dialysis is required instead: (1) familial dysalbuminemic hyperthyroxinemia, where total T4 is genetically elevated but free T4 is normal — T7 will over-correct and may falsely suggest hyperthyroidism; (2) non-thyroidal illness, where binding protein and conversion changes invalidate the TBG-correction assumption underlying the index; (3) TBG at extremes — very high at term pregnancy or very low in nephrotic syndrome — where the correction factor may not fully account for the degree of binding-protein shift. In these situations, the T7 index is not the appropriate tool.

The legacy T7 index is a backup tool, not the preferred modern standard. Guidelines favor pairing TSH with a direct free T4 measurement when available; T7 remains clinically useful when binding protein changes or assay interferences make direct free T4 results unreliable, or when historical T7 values are being trended for continuity.

Trending TSH alongside T7 or free T4 across months makes it easier to separate a one-off blip from a real shift, and to confirm that a dose adjustment has achieved its intended effect. A comprehensive thyroid panel — TSH, total T4, T3 uptake, free T3, and TPO antibodies where indicated — gives the full picture that a single index cannot. That pattern-based approach, aligned with symptoms and draw-condition consistency, is how thyroid data becomes actionable. Superpower is built around that approach — advanced biomarker testing interpreted in context, so results inform decisions rather than generate noise.